Organic Chemical – Page 6

Novartis CEO on $12B Avidity Deal: ‘Could Have Been Twice as Big’

2 months ago talkbio0Tagged Acquisition, Avidity Biosciences, financial outlook, growth strategy, Merger, Neuromuscular Diseases, Novartis, RNA, SpinCo ', Vas Narasimhan

Novartis; Avidity Biosciences; Vas Narasimhan; merger; acquisition; biotech; RNA therapeutics; $12 billion deal; neuromuscular diseases; SpinCo; financial outlook; growth strategy

Novartis to Acquire RNA Drugmaker Avidity Biosciences in $12 Billion Deal

2 months ago talkbio0Tagged 2026, Acquisition, AOC, Avidity Biosciences, Closed, Muscular Dystrophy, Duchenne, Muscular Dystrophy, Facioscapulohumeral, MYOTONIC DYSTROPHY 1, Neuromuscular Diseases, Novartis, Platform, RNA therapeutics, SpinCo ', xRNA

Novartis; Avidity Biosciences; acquisition; RNA therapeutics; neuromuscular diseases; Duchenne muscular dystrophy; myotonic dystrophy type 1; facioscapulohumeral muscular dystrophy; AOC platform; SpinCo; biotech; xRNA strategy; 2026 closing

FDA Approves GSK’s Blenrep for Multiple Myeloma Treatment, Marking a Market Return

2 months ago talkbio0Tagged Approved, Blenrep, bortezomib, dexamethasone, Multiple Myeloma, SmithKline Beecham, United States Food and Drug Administration

Blenrep; GSK; FDA Approval; Multiple Myeloma; Bortezomib; Dexamethasone

Roche in Talks With US on Drug Pricing; Sets Out Pipeline and Dealmaking Ambitions

2 months ago talkbio0Tagged Benefit, dealmaking, direct-to-consumer sales, drug price, gene therapy, Government, Hemlibra, Investments, manager, Manufacturing, Ocrevus, Pharmaceutical Services, pipeline, R&D, Roche (company), U.S., Vabysmo

Roche; drug pricing; US government; pharmacy benefit managers; direct-to-consumer sales; pipeline; dealmaking; US investment; manufacturing; gene therapy; R&D; Ocrevus; Hemlibra; Vabysmo

Flagship Pioneering Launches Expedition Medicines to Revolutionize Small-Molecule Drug Discovery with AI

2 months ago talkbio0Tagged AI drug discovery, covalent binding drugs, executive leadership, Expedition Medicines, Flagship, generative design, Lila Sciences, Small Molecule, startup

Flagship Pioneering; Expedition Medicines; AI drug discovery; small molecules; covalent binding drugs; Lila Sciences; biotech startup; generative design; executive leadership

Exelixis’ Kinase Blocker Zanzalintinib Sets New Survival Standard in Third-Line Metastatic Colorectal Cancer, Paving Way for FDA Review

2 months ago talkbio0Tagged Colorectal Carcinoma, Exelixis, kinase inhibitor [EPC], Overall Survival, regorafenib, STELLAR-303 trial, Submission, Tecentriq, Third line treatment, United States Food and Drug Administration, zanzalintinib

Exelixis; zanzalintinib; kinase inhibitor; colorectal cancer; STELLAR-303 trial; Tecentriq; regorafenib; overall survival; third-line therapy; FDA submission